Literature DB >> 17848867

Dextromethorphan as a potential neuroprotective agent with unique mechanisms of action.

Linda L Werling1, Edward C Lauterbach, Ursula Calef.   

Abstract

BACKGROUND: Dextromethorphan (DM) is a widely-used antitussive. DM's complex central nervous system (CNS) pharmacology became of interest when it was discovered to be neuroprotective due to its low-affinity, uncompetitive N-methyl-D-aspartate (NMDA) receptor antagonism. REVIEW
SUMMARY: Mounting preclinical evidence has proven that DM has important neuroprotective properties in various CNS injury models, including focal and global ischemia, seizure, and traumatic brain injury paradigms. Many of these protective actions seem functionally related to its inhibitory effects on glutamate-induced neurotoxicity via NMDA receptor antagonist, sigma-1 receptor agonist, and voltage-gated calcium channel antagonist actions. DM's protection of dopamine neurons in parkinsonian models may be due to inhibition of neurodegenerative inflammatory responses. Clinical findings are limited, with preliminary evidence indicating that DM protects against neuronal damage. Negative findings seem to relate to attainment of inadequate DM brain concentrations. Small studies have shown some promise for treatment of perioperative brain injury, amyotrophic lateral sclerosis, and symptoms of methotrexate neurotoxicity. DM safety/tolerability trials in stroke, neurosurgery, and amyotrophic lateral sclerosis patients demonstrated a favorable safety profile. DM's limited clinical benefit is proposed to be associated with its rapid metabolism to dextrorphan, which restricts its central bioavailability and therapeutic utility. Systemic concentrations of DM can be increased via coadministration of low-dose quinidine (Q), which reversibly inhibits its first-pass elimination. Potential drug interactions with DM/Q are discussed.
CONCLUSIONS: Given the compelling preclinical evidence for neuroprotective properties of DM, initial clinical neuroprotective findings, and clinical demonstrations that the DM/Q combination is well tolerated, this strategy may hold promise for the treatment of various acute and degenerative neurologic disorders.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17848867     DOI: 10.1097/NRL.0b013e3180f60bd8

Source DB:  PubMed          Journal:  Neurologist        ISSN: 1074-7931            Impact factor:   1.398


  22 in total

1.  Memantine protects rats treated with intrathecal methotrexate from developing spatial memory deficits.

Authors:  Peter D Cole; Veena Vijayanathan; Nafeeza F Ali; Mark E Wagshul; Eric J Tanenbaum; Jeremy Price; Vidhi Dalal; Maria E Gulinello
Journal:  Clin Cancer Res       Date:  2013-07-05       Impact factor: 12.531

2.  Repeated, high-dose dextromethorphan treatment decreases neurogenesis and results in depression-like behavior in rats.

Authors:  Kai Ting Po; Andrew Man-Hong Siu; Benson Wui-Man Lau; Jackie Ngai-Man Chan; Kwok-Fai So; Chetwyn C H Chan
Journal:  Exp Brain Res       Date:  2015-05-05       Impact factor: 1.972

3.  Characterization of pulmonary sigma receptors by radioligand binding.

Authors:  John R Lever; Tyler P Litton; Emily A Fergason-Cantrell
Journal:  Eur J Pharmacol       Date:  2015-05-22       Impact factor: 4.432

Review 4.  Targeting ligand-operated chaperone sigma-1 receptors in the treatment of neuropsychiatric disorders.

Authors:  Teruo Hayashi; Shang-Yi Tsai; Tomohisa Mori; Michiko Fujimoto; Tsung-Ping Su
Journal:  Expert Opin Ther Targets       Date:  2011-03-05       Impact factor: 6.902

Review 5.  Cholinergic System and Its Therapeutic Importance in Inflammation and Autoimmunity.

Authors:  Namrita Halder; Girdhari Lal
Journal:  Front Immunol       Date:  2021-04-15       Impact factor: 7.561

6.  Low dose dextromethorphan attenuates moderate experimental autoimmune encephalomyelitis by inhibiting NOX2 and reducing peripheral immune cells infiltration in the spinal cord.

Authors:  Olga V Chechneva; Florian Mayrhofer; Daniel J Daugherty; David E Pleasure; Jau-Shyong Hong; Wenbin Deng
Journal:  Neurobiol Dis       Date:  2011-06-24       Impact factor: 5.996

7.  Inhibition of 3,4-methylenedioxymethamphetamine metabolism leads to marked decrease in 3,4-dihydroxymethamphetamine formation but no change in serotonin neurotoxicity: implications for mechanisms of neurotoxicity.

Authors:  Melanie Mueller; Jie Yuan; Concepcion Maldonado Adrian; Una D McCann; George A Ricaurte
Journal:  Synapse       Date:  2011-03-28       Impact factor: 2.562

8.  Prophylactic and therapeutic functions of drug combinations against noise-induced hearing loss.

Authors:  Jianxin Bao; Michelle Hungerford; Randi Luxmore; Dalian Ding; Ziyu Qiu; Debin Lei; Aizhen Yang; Ruqiang Liang; Kevin K Ohlemiller
Journal:  Hear Res       Date:  2013-06-18       Impact factor: 3.208

9.  Dextromethorphan inhibits osteoclast differentiation by suppressing RANKL-induced nuclear factor-κB activation.

Authors:  Karl Wu; Tzu-Hung Lin; Houng-Chi Liou; Dai-Hua Lu; Yi-Ru Chen; Wen-Mei Fu; Rong-Sen Yang
Journal:  Osteoporos Int       Date:  2013-02-12       Impact factor: 4.507

Review 10.  The sigma-1 receptor: roles in neuronal plasticity and disease.

Authors:  Saïd Kourrich; Tsung-Ping Su; Michiko Fujimoto; Antonello Bonci
Journal:  Trends Neurosci       Date:  2012-10-23       Impact factor: 13.837

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.